Join our Nursing Review Community! Subscribe below. Its Free!

Join NurseReview.Org Community!

Get Connected With Other Nurses All Over The World! Its Free!! Enter your email to receive the Nursing Board Exam NLE Quick Result!


         Nursing Board Exam Result Subscribers PRC December NLE Quick Results Subscription

NurseReview.Org helps nurses all over the world keep in touch with each other. We provide an interactive environment where nurses can share their experience, ask questions regarding issues, provide assistance, etc.

If you want to be informed through email regarding NLE RESULTS, Nursing News, Retrogression Updates, New Nursing Board Exam Question & Answer, Latest Updates Regarding Nclex, please subscribe to us by filling in your email address above.

NOTE: You email address will be kept private and will not be distributed to spammers.
com/albums/dd234/jben501/philippinenurses/need_help_nursing.jpg" border="0" width="400" height="400" />

Monday, October 29, 2007

Diabetes Mellitus :: Medical Surgical Nursing :: Review For Nursing Licensure Examination

If you're new here, you may want to subscribe to our RSS feed. One advantage of subscribing to RSS feeds is that you don't have to constantly re-visit this site to check for updates within specific sections you might be interested in because your browser or Feed reader will do this for you automatically on a regular basis plus you can even get email notification. Thank you so much. Enjoy!

Related Articles for Nursing Licensure Examination Review

Anatomy & Physiology
-Introduction to Anatomy & Physiology
-Gynecological Anatomy & Physiology
-Lymphatics And Repiratory System

Fundamentals Of Nursing
-Activity And Exercise
-Loss And Grief

-Nursing Rehabilitation
-Pain And Comfort
-Rest And Sleep

Medical Surgical Nursing
-Angioplasty vs. Bypass
-Cancer Nursing
-Cardiovascular Hematologic
-Common Laboratory Procedures
-Diabetes Mellitus
-Emergency Nursing And Critical Care
-Gastrointestinal System
-Genito Urinary System
-Integumentary System
-Musculoskeletal System
-Neurology Part 1
-Neurology Part 2

Diabetes Mellitus :: Medical Surgical Nursing :: Review For Nursing Licensure Examination Slide Transcript
Slide 1: Nurse Licensure Examination Review Diabetes Mellitus

Slide 2: Diabetes Mellitus A group of metabolic diseases  characterized by elevated levels of glucose in the blood resulting from defects in insulin secretion, insulin action, insulin receptors or any combination of conditions.

Slide 3: Diabetes Mellitus A chronic disorder of impaired  glucose metabolism, protein and fat metabolism

Slide 4: Diabetes Mellitus  BASIC PATHOLOGY : Insulin problem (deficiency or impaired action)

Slide 5: Diabetes Mellitus Insulin is a hormone secreted  by the BETA cells of the pancreas  Stimulus of insulin- HYPERGLYCEMIA

Slide 6: Diabetes Mellitus  Action of insulin: it promotes entry of Glucose into the body cells by binding to the insulin receptor in the cell membrane

Slide 7: INSULIN : Physiology Insulin Metabolic Functions:  1. Transports and metabolizes GLUCOSE  2. Promotes GLYCOGENESIS  3. Promotes GLYCOLYSIS  4. Enhances LIPOGENESIS  5. Accelerates PROTEIN SYNTHESIS

Slide 8: Diabetes Mellitus RISK FACTORS for Diabetes Mellitus  1. Family History of diabetes  2. Obesity  3. Race/Ethnicity

Slide 9: Diabetes Mellitus RISK FACTORS for Diabetes Mellitus  4. Age of more than 45  5. Previously unidentified IFG/IGT  6. Hypertension

Slide 10: Diabetes Mellitus RISK FACTORS for Diabetes Mellitus  7. Hyperlipidemia  8. History of Gestational Diabetes Mellitus

Slide 11: Diabetes Mellitus CLASSIFICATION OF DM 1. Type 1 DM Insulin dependent Diabetes Mellitus  2. Type 2 DM Non-insulin dependent Diabetes Mellitus  3. Gestational DM Diabetes Mellitus diagnosed during pregnancy  4. DM associated with other conditions or syndromes

Slide 12: Diabetes Mellitus CLASSIFICATION OF DM 1. Type 1 DM  Insulin dependent Diabetes Mellitus

Slide 13: Diabetes Mellitus CLASSIFICATION OF DM 2. Type 2 DM  Non-insulin dependent Diabetes Mellitus

Slide 14: Diabetes Mellitus CLASSIFICATION OF DM 3. Gestational DM  Diabetes Mellitus diagnosed during pregnancy

Slide 15: Diabetes Mellitus CLASSIFICATION OF DM 4. DM associated with other conditions or syndromes

Slide 16: Diabetes Mellitus Other types of DM  1. Impaired Glucose Tolerance  2. Impaired Fasting Glucose  3. Pre-diabetes

Slide 17: TYPE 1- Diabetes Mellitus This type of DM is characterized by the destruction of the pancreatic beta cells

Slide 18: TYPE 1- Diabetes Mellitus Etiology: 1. Genetic susceptibility- HLA DR3 and DR4 2. Autoimmune response 3. Toxins, unidentified viruses and environmental factors

Slide 19: TYPE 1- Diabetes Mellitus PATHOPHYSIOLOGY  Destruction of BETA cells decreased insulin production  uncontrolled glucose production by the liver hyperglycemia  signs and symptoms

Slide 20: TYPE 1- Diabetes Mellitus PATHOPHYSIOLOGY CLASSIC P’s  Polyuria  Polydipsia  Polyphagia

Slide 21: TYPE 2- Diabetes Mellitus A type of DM characterized  by insulin resistance and impaired insulin production

Slide 22: TYPE 2- Diabetes Mellitus Etiology: 1. Unknown 2. Probably genetic and obesity

Slide 23: TYPE 2- Diabetes Mellitus PATHOPHYSIOLOGY  Decreased sensitivity of insulin receptor to insulin  less uptake of glucose  HYPERGLYCEMIA

Slide 24: TYPE 2- Diabetes Mellitus PATHOPHYSIOLOGY  Decreased insulin production  diminished insulin action  hyperglycemia  signs and symptoms

Slide 25: TYPE 2- Diabetes Mellitus PATHOPHYSIOLOGY  BUT (+) insulin in small amount  prevent breakdown of fats  DKA is unusual

Slide 26: GESTATIONAL Diabetes Mellitus Any degree of glucose  intolerance with its onset during pregnancy  Usually detected between 24- 28 week gestation th

Slide 27: GESTATIONAL Diabetes Mellitus Blood glucose returns to normal  after delivery of the infant NEVER administer ORAL  HYPOGLYCEMIC AGENTS to PREGNANT MOTHERS!

Slide 28: Diabetes Mellitus ASSESSMENT FINDINGS  1. Classic 3 P’s  2. Fatigue  3. Body weakness

Slide 29: Diabetes Mellitus ASSESSMENT FINDINGS  4. Visual changes  5. Slow wound healing  6. Recurrent skin and mucus membrane infections

Slide 30: Diabetes Mellitus DIAGNOSTIC TESTS  1. FBS- > 126  2. RBS- >200  3. OGTT- > 200

Slide 31: Diabetes Mellitus DIAGNOSTIC TESTS  4. HgbA1- for monitoring!!  5. Urine glucose  6. Urine ketones

Slide 32: Diabetes Mellitus DIAGNOSTIC CRITERIA  1. FBS equal to or greater than 126 mg/dL (7.0mmol/L)  (Normal 8 hour FBS- 80- 109 mg/dL)

Slide 33: Diabetes Mellitus DIAGNOSTIC CRITERIA  2. OGTT value 1 and 2 hours post-prandial equal to or greater than 200 mg/dL  Normal OGTT 1 and 2 hours post-prandial- is  140 mg/dL

Slide 34: Diabetes Mellitus DIAGNOSTIC CRITERIA  3.RBS of equal to or greater than 200 mg/dL PLUS the 3 P’s

Slide 35: Diabetes Mellitus NURSING MANAGEMENT OF DM  The main goal is to NORMALIZE insulin activity and blood glucose level by:

Slide 36: Diabetes Mellitus NURSING MANAGEMENT OF DM 1. Nutritional modification 2. Regular Exercise 3. Regular Glucose Monitoring 4. Drug therapy 5. Client Education

Slide 37: Diabetes Mellitus The Patient with DM HISTORY  Symptoms and characteristics  PHYSICAL EXAMINATION  VS, BMI, Fundoscopy, Neuro  LABORATORY EXAMINATION  FBS, RBS, HgbA1c, lipid profile, ECG, UA  REFERRALS  Ophthalmologist, Podiatrist, Dietician, etc.. 

Slide 38: Diabetes Mellitus The Patient with DM HISTORY   Symptoms and characteristics PHYSICAL EXAMINATION   VS, BMI, Fundoscopy, and Neuro assessment

Slide 39: Diabetes Mellitus The Patient with DM LABORATORY EXAMINATION   FBS, RBS, HgbA1c, lipid profile, ECG, and Urinalysis REFERRALS   Ophthalmologist, Podiatrist, Dietician, etc..

Slide 40: DM Nutritional management

Slide 41: Diabetes Mellitus NUTRITIONAL MANAGEMENT  1.Review the patient’s diet history to identify eating habits and lifestyle  2. Coordinate with the dietician in meal planning for weight loss

Slide 42: Diabetes Mellitus NUTRITIONAL MANAGEMENT  3. Plan for the caloric intake distributed as follows- CHO 50-60%; Fats 20-30%; and Proteins 10-20%  4. Advise moderation in alcohol intake  5. Using artificial sweeteners is acceptable

Slide 43: DM Exercise management

Slide 44: Diabetes Mellitus EXERCISE Management  1. Teach that exercise can lower the blood glucose level  2. Diabetics must first control the glucose level before initiating exercise programs.

Slide 45: Diabetes Mellitus EXERCISE Management 3. Offer extra food /calories  before engaging in exercise 4. Offer snacks at the end of the  exercise period if patient is on insulin treatment.

Slide 46: Diabetes Mellitus EXERCISE Management  5. Advise that exercise should be done at the same time every day, preferably when blood glucose levels are at their peak

Slide 47: Diabetes Mellitus EXERCISE Management 6. Regular exercise, not sporadic  exercise, should be encouraged. 7. For most patient, WALKING  is the safe and beneficial form of exercise

Slide 48: Glucose Self Monitoring

Slide 49: Diabetes Mellitus GLUCOSE MONITORING Self-monitoring of blood glucose  (SMBG) enables the patient to adjust the treatment regimen to obtain optimal glucose control

Slide 50: Diabetes Mellitus GLUCOSE MONITORING  Most common method involves obtaining a drop of capillary blood applied to a test strip.  The usual recommended frequency is TWO-FOUR times a day.

Slide 51: Diabetes Mellitus When is it done?  At the peak action time of the medication to evaluate the need for adjustments.  To evaluate BASAL insulin  test before meals

Slide 52: Diabetes Mellitus When is it done?  To titrate bolus or regular and lispro test 2 hours after meals.  To evaluate the glucose level of those taking ORAL hypoglycemics  test before and two hours after meals.

Slide 53: Diabetes Mellitus Monitoring therapy Testing the glycosylated  hemoglobin (HbA1c) This glycosylated hemoglobin  refers to the blood test that reflects the average blood glucose over a period of TWO to THREE months.

Slide 54: Diabetes Mellitus Monitoring therapy  Normal value is 4 to 6 %  No patient preparation is needed for this testing  Done to monitor therapy

Slide 55: Diabetes Mellitus Urine testing for glucose  Benedict’s test 

Slide 56: Diabetes Mellitus Urine testing for ketones   Ketones are by-products of fat breakdown

Slide 57: Diabetes Mellitus Urine testing for ketones   This is performed whenever TYPE 1 DM have glucosuria or persistent elevation of blood glucose, during illness, and in gestational diabetes

Slide 58: DM Drug therapy

Slide 59: Diabetes Mellitus DRUG THERAPY and MANAGEMENT Usually, this type of management is  employed if diet modification and exercise cannot control the blood glucose level.

Slide 60: Diabetes Mellitus DRUG THERAPY and MANAGEMENT Because the patient with TYPE  1 DM cannot produce insulin, exogenous insulin must be administered for life.

Slide 61: Diabetes Mellitus DRUG THERAPY and MANAGEMENT TYPE 2 DM may have  decreased insulin production, ORAL agents that stimulate insulin production are usually employed.

Slide 62: Diabetes Mellitus PHARMACOLOGIC INSULIN This may be grouped into several  categories according to: 1. Source- Human, pig, or cow 2. Onset of action- Rapid-acting, short-acting, intermediate-acting, long-acting and very long acting

Slide 63: Diabetes Mellitus PHARMACOLOGIC INSULIN This may be grouped into several  categories according to: 3. Pure or mixed concentration 4. Manufacturer of drug

Slide 64: Diabetes Mellitus GENERALITIES  1. Human insulin preparations have a shorter duration of action than animal source

Slide 65: Diabetes Mellitus GENERALITIES  2. Animal sources of insulin have animal proteins that may trigger allergic reaction and they may stimulate antibody production that may bind the insulin, slowing the action

Slide 66: Diabetes Mellitus  3. ONLY Regular insulin can be used INTRAVENOUSLY!

Slide 67: Diabetes Mellitus 4. Insulin are measured in  INTERNATIONAL UNITS or “iu” 5. There is a specified insulin  injection calibrated in units

Slide 68: Diabetes Mellitus RAPID ACTING INSULIN  Lispro (Humalog) and Insulin Aspart (Novolog)  Produces a more rapid effect and with a shorter duration than any other insulin preparation

Slide 69: Diabetes Mellitus RAPID ACTING INSULIN  ONSET- 5-15 minutes  PEAK- 1 hour  DURATION- 3 hours  Instruct patient to eat within 5 to 15 minutes after injection

Slide 70: Diabetes Mellitus REGULAR INSULIN  Also called Short-acting insulin  “R”  Usually Clear solution administered 30 minutes before a meal

Slide 71: Diabetes Mellitus REGULAR INSULIN  ONSET- 30 minutes to 1 hour  PEAK- 2 to 3 hours  DURATION- 4 to 6 hours

Slide 72: Diabetes Mellitus INTERMEDIATE ACTING INSULIN  Called “NPH” or “LENTE”  Appears white and cloudy

Slide 73: Diabetes Mellitus INTERMEDIATE ACTING INSULIN  ONSET- 2-4 hours  PEAK- 4 to 6-12 hours  DURATION- 16-20 hours

Slide 74: Diabetes Mellitus LONG- ACTING INSULIN  “UltraLENTE”  Referred to as “peakless” insulin

Slide 75: Diabetes Mellitus LONG- ACTING INSULIN  ONSET- 6-8 hours  PEAK- 12-16 hours  DURATION- 20-30 hours

Slide 76: Diabetes Mellitus HEALTH TEACHING Regarding Insulin SELF- Administration  1. Insulin is administered at home subcutaneously

Slide 77: Diabetes Mellitus HEALTH TEACHING Regarding Insulin SELF- Administration  2. Cloudy insulin should be thoroughly mixed by gently inverting the vial or ROLLING between the hands

Slide 78: Diabetes Mellitus HEALTH TEACHING Regarding Insulin SELF- Administration  3. Insulin NOT IN USE should be stored in the refrigerator, BUT avoid freezing/extreme temperature

Slide 79: Diabetes Mellitus 4. Insulin IN USE should be  kept at room temperature to reduce local irritation at the injection site

Slide 80: Diabetes Mellitus 5. INSULIN may be kept at  room temperature up to 1 month

Slide 81: Diabetes Mellitus 6. Select syringes that match  the insulin concentration.  U-100 means 100 units per mL

Slide 82: Diabetes Mellitus  7. Instruct the client to draw up the REGULAR (clear) Insulin FIRST before drawing the intermediate acting (cloudy) insulin

Slide 83: Diabetes Mellitus 8. Pre-filled syringes can be  prepared and should be kept in the refrigerator with the needle in the UPRIGHT position to avoid clogging the needle

Slide 84: Diabetes Mellitus 9. The four main areas for  insulin injection are- ABDOMEN, UPPER ARMS, THIGHS and HIPS

Slide 86: Diabetes Mellitus Insulin is absorbed fastest in the  abdomen and slowest in the hips Instruct the client to rotate the areas  of injection, but exhaust all available sites in one area first before moving into another area.

Slide 87: Diabetes Mellitus 10. Alcohol may not be used to  cleanse the skin  11. Utilize the subcutaneous injection technique- commonly, a 45-90 degree angle.

Slide 88: Diabetes Mellitus 12. No need to instruct for  aspirating the needle  13. Properly discard the syringe after use.

Slide 89: Diabetes Mellitus T-I-E Test blood Inject insulin  Eat food

Slide 90: Diabetes Mellitus COMPLICATIONS OF INSULIN THERAPY 1. Local allergic reactions  Redness, swelling, tenderness and induration appearing 1-2 hours after injection  Usually occurs in the beginning stage of therapy

Slide 91: Diabetes Mellitus COMPLICATIONS OF INSULIN THERAPY 1. Local allergic reactions  Disappears with continued use  Antihistamine can be given 1 hour before injection time  Porcine and bovine insulin preparations have a higher tendency to produce this reaction.

Slide 92: Diabetes Mellitus 2. SYSTEMIC ALLERGIC REACTIONS  Very rare  Generalized urticaria is the manifestation  Treatment is desensitization

Slide 93: Diabetes Mellitus COMPLICATIONS OF INSULIN THERAPY 3. INSULIN DYSTROPHY  A localized reaction in the form of lipoatrophy or lipohypertrophy

Slide 94: Diabetes Mellitus Lipoatrophy- loss of  subcutaneous fat usually caused by the utilization of animal insulin

Slide 95: Diabetes Mellitus  Lipohypertrophy- development of fibrofatty masses, usually caused by repeated use of injection site

Slide 96: Diabetes Mellitus 4. INSULIN RESISTANCE  Most commonly caused by OBESITY  Defined as daily insulin requirement of more than 200 units  Management- Steroids and use of more concentrated insulin

Slide 97: Diabetes Mellitus 5. MORNING HYPERGLYCEMIA  Elevated blood sugar upon arising in the morning  Caused by insufficient level of insulin  DAWN phenomenon  SOMOGYI effect  INSULIN WANING

Slide 98: Diabetes Mellitus DAWN PHENOMENON  Relatively normal blood glucose until about 3 am, when the glucose level begins to RISE  Results from the nightly surges of GROWTH HORMONE secretion  Management: Bedtime injection of NPH

Slide 99: Diabetes Mellitus SOMOGYI EFFECT  Normal or elevated blood glucose at bedtime, decrease blood glucose at 2-3 am due to hypoglycemic levels and a subsequent increase in blood glucose (rebound hypergycemia)

Slide 100: Diabetes Mellitus SOMOGYI EFFECT  Nocturnal hypoglycemia followed by rebound hyperglycemia

Slide 101: Diabetes Mellitus SOMOGYI EFFECT  Due to the production of counter regulatory hormones- glucagon. cortisol and epinephrine  Management- decrease evening dose of NPH or increase bedtime snack

Slide 102: Diabetes Mellitus INSULIN WANING Progressive rise in blood glucose  from bedtime to morning Seen when the NPH evening dose is  administered before dinner Management: Move the insulin  injection to bedtime

Slide 103: Diabetes Mellitus ORAL HYPOGLYCEMIC AGENTS These may be effective when  used in TYPE 2 DM that cannot be treated with diet and exercise These are NEVER used in  pregnancy!

Slide 104: Diabetes Mellitus ORAL HYPOGLYCEMIC AGENTS  There are several agents:  Sulfonylureas  Biguanides  Alpha-glucosidase inhibitors  Thiazolidinediones  Meglitinides

Slide 105: Diabetes Mellitus SULFONYLUREAS  MOA- stimulates the beta cells of the pancreas to secrete insulin  Classified as to generations- first and second generations

Slide 106: Diabetes Mellitus SULFONYLUREAS  FIRST GENERATION- Acetoheximide, Chlorpropamide, Tolazamide and Tolbutamide  SECOND GENERATION- Glipizide, Glyburide, Glibenclamide, Glimepiride

Slide 107: Diabetes Mellitus: Sulfonylureas The most common side –effects  of these medications are Gastro- intestinal upset and dermatologic reactions. HYPOGLYCEMIA is also a  very important side-effect

Slide 108: Diabetes Mellitus: Sulfonylureas Chlorpropamide has a very long  duration of action. This also produces a disulfiram-like reaction when taken with alcohol Second generation drugs have  shorter duration with metabolism in the kidney and liver and are the choice for elderly patients

Slide 109: Diabetes Mellitus BIGUANIDES  MOA- Facilitate the action of insulin on the peripheral receptors  These can only be used in the presence of insulin

Slide 110: Diabetes Mellitus BIGUANIDES= “formin”  They have no effect on the beta cells of the pancreas  Metformin (Glucophage) and Phenformin are examples

Slide 111: Diabetes Mellitus: Biguanides The most important side effect  is LACTIC ACIDOSIS!  These are not given to patient with renal impairment

Slide 112: Diabetes Mellitus: Biguanides These drugs are usually given  with a sulfonylurea to enhance the glucose-lowering effect more than the use of each drug individually

Slide 113: Diabetes Mellitus ALPHA-GLUCOSIDASE INHIBITORS  MOA- Delay the absorption of glucose in the GIT  Result is a lower post-prandial blood glucose level  They do not affect insulin secretion or action!  Side-effect: DIARRHEA and FLATULENCE

Slide 114: Diabetes Mellitus Examples of AGI are Acarbose  and Miglitol They are not absorbed  systemically and are very safe They can be used alone or in  combination with other OHA

Slide 115: Diabetes Mellitus Side-effect if used with other  drug is HYPOGLYCEMIA  Note that sucrose absorption is impaired and IV glucose is the therapy for the hypoglycemia

Slide 116: Diabetes Mellitus THIAZOLIDINEDIONES  MOA- Enhance insulin action at the receptor site  They do not stimulate insulin secretion

Slide 117: Diabetes Mellitus THIAZOLIDINEDIONES Examples- Rosiglitazone, Pioglitazone  These drugs affect LIVER  FUNCTION Can cause resumption of OVULATION  in peri-menopausal anovulatory women

Slide 118: Diabetes Mellitus MEGLITINIDES  MOA- Stimulate the secretion of insulin by the beta cells  Examples- Repaglinide and Nateglinide

Slide 119: Diabetes Mellitus MEGLITINIDES They have a shorter duration  and fast action Should be taken BEFORE meals  to stimulate the release of insulin from the pancreas

Slide 120: Diabetes Mellitus MEGLITINIDES  Principal side-effect of meglitinides- hypoglycemia  Can be used alone or in combination

Slide 121: Diabetes Mellitus ACUTE COMPLICATIONS OF DM  Hypoglycemia  Diabetic ketoacidosis  Hyperglycemic hyperosmolar non- ketotic syndrome (HHNS)

Slide 122: Diabetes Mellitus CHRONIC COMPLICATIONS OF DM Macrovascular complications- MI,  Stroke, Atherosclerosis, CAD, and Peripheral vascular disease Microvascular complications- micro-  angiopathy, retinopathy, nephropathy Peripheral neuropathy 

Slide 124: Diabetes Mellitus HYPOGLYCEMIA Blood glucose level less than 50 to 60  mg/dL Causes: Too much insulin/OHA, too  little food and excessive physical activity Mild- 40-60  Moderate- 20-40  Severe- less than 20 

Slide 125: HYPOGLYCEMIA ASSESSMENT FINDINGS 1. Sympathetic manifestations-  sweating, tremors, palpitations, nervousness, tachycardia and hunger

Slide 126: HYPOGLYCEMIA ASSESSMENT FINDINGS 2. CNS manifestations- inability to  concentrate, headache, lightheadedness, confusion, memory lapses, slurred speech, impaired coordination, behavioral changes, double vision and drowsiness


Slide 129: HYPOGLYCEMIA DIAGNOSTIC FINDINGS  RBS- less than 50-60 mg/dL level

Slide 130: HYPOGLYCEMIA Nursing Interventions  1. Immediate treatment with the use of foods with simple sugar- glucose tablets, fruit juice, table sugar, honey or hard candies

Slide 131: HYPOGLYCEMIA Nursing Interventions  2. For unconscious patients- glucagon injection 1 mg IM/SQ; or IV 25 to 50 mL of D50/50

Slide 132: HYPOGLYCEMIA Nursing Interventions  3. re-test glucose level in 15 minutes and re-treat if less than 75 mg/dL  4. Teach patient to refrain from eating high-calorie, high-fat desserts

Slide 133: HYPOGLYCEMIA Nursing Interventions  5. Advise in-between snacks, especially when physical activity is increased  6. Teach the importance of compliance to medications

Slide 134: Diabetic Ketoacidosis This is cause by the absence of insulin  leading to fat breakdown and production of ketone bodies Three main clinical features:   1. HYPERGLYCEMIA  2. DEHYDRATION & electrolyte loss  3. ACIDOSIS

Slide 135: DKA PATHOPHYSIOLOGY  No insulin reduced glucose breakdown and increased liver glucose production  Hyperglycemia

Slide 136: DKA PATHOPHYSIOLOGY  Hyperglycemia kidney attempts to excrete glucose  increased osmotic load  diuresis  Dehydration

Slide 137: DKA PATHOPHYSIOLOGY  No glucose in the cell fat is broken down for energy  ketone bodies are produced Ketoacidosis

Slide 138: DKA Risk factors  1. infection or illness- common  2. stress  3. undiagnosed DM  4. inadequate insulin, missed dose of insulin

Slide 139: DKA ASSESSMENT FINDINGS  1. 3 P’s  2. Headache, blurred vision and weakness  3. Orthostatic hypotension

Slide 140: DKA ASSESSMENT FINDINGS  4. Nausea, vomiting and abdominal pain  5. Acetone (fruity) breath  6. Hyperventilation or KUSSMAUL’s breathing


Slide 142: Hyperglycemia

Slide 143: DKA LABORATORY FINDINGS  1. Blood glucose level of 300- 800 mg/dL  2. Urinary ketones

Slide 144: DKA LABORATORY FINDINGS  3. ABG result of metabolic acidosis- LOW pH, LOW pCO2 as a compensation, LOW bicarbonate  4. Electrolyte imbalances- potassium levels may be HIGH due to acidosis and dehydration

Slide 145: DKA NURSING INTERVENTIONS  1. Assist in the correction of dehydration  Up to 6 liters of fluid may be ordered for infusion, initially NSS then D5W  Monitor hydration status  Monitor I and O  Monitor for volume overload

Slide 146: DKA NURSING INTERVENTIONS  2. Assist in restoring Electrolytes  Kidney function is FIRST determined before giving potassium supplements!

Slide 147: DKA NURSING INTERVENTIONS  3. Reverse the Acidosis  REGULAR insulin injection is ordered IV bolus 5-10 units  The insulin is followed by drip infusion in units per hour  BICARBONATE is not used!

Slide 148: HHNS A serious condition in which  hyperosmolarity and extreme hyperglycemia predominate Ketosis is minimal  Onset is slow and takes hours to  days to develop

Slide 149: HHNS PATHOPHYSIOLOGY  Lack of insulin action or Insulin resistance  hyperglycemia  Hyperglycemia osmotic diuresis  loss of water and electrolytes

Slide 150: HHNS PATHOPHYSIOLOGY  Insulin is too low to prevent hyperglycemia but enough to prevent fat breakdown  Occurs most commonly in type 2 DM, ages 50-70

Slide 151: HHNS Precipitating factors  1. Infection  2. Stress  3. Surgery  4. Medication like thiazides  5. Treatment like dialysis

Slide 152: HHNS ASSESSMENT FINDINGS  1. Profound dehydration  2. Hypotension  3. Tachycardia  4. Altered sensorium  5. Seizures and hemiparesis

Slide 153: HHNS DIAGNOSTIC TESTS  1. Blood glucose- 600 to 1,200 mg/dL  2. Blood osmolality- 350 mOsm/L  3. Electrolyte abnormalities

Slide 154: HHNS NURSING INTERVENTIONS  Approach is similar to the DKA  1. Correction of Dehydration by IVF  2. Correction of electrolyte imbalance by replacement therapy

Slide 155: HHNS NURSING INTERVENTIONS  3. Administration of insulin injection and drips  4. Continuous monitoring of urine output

Slide 156: MACROVASCULAR CX Nursing management  1. Diet modification  2. Exercise

Slide 157: MACROVASCULAR CX Nursing management  3. Prevention and treatment of underlying conditions such as MI, CAD and stroke  4. Administration of prescribed medications for hypertension, hyperlipidemia and obesity

Slide 158: MICROVASCULAR CX Retinopathy- a painless deterioration  of the small blood vessels in the retina, may be classified as to background retinopathy, pre-proliferative and proliferative retinopathy Permanent vision changes and  blindness can occur

Slide 159: MICROVASCULAR CX Retinopathy-ASSESSMENT FINDINGS  Blurry vision  Spotty vision  Asymptomatic

Slide 160: MICROVASCULAR CX Retinopathy: Diagnostic findings  1. Fundoscopy  2. Fluorescein angiography  Painless procedure  Side-effects- discoloration of the skin and urine for 12 hours, some allergic reactions, nausea  Flash of camera may be slightly uncomfortable

Slide 161: MICROVASCULAR CX NURSING INTERVENTIONS  1. Assist in diagnostic procedure  2. Assist in the preparation for surgery- laser photocoagulation

Slide 162: MICROVASCULAR CX NURSING INTERVENTIONS  3. Health teaching regarding prevention of retinopathy by regular ophthalmic examinations, good glucose control and self- management of eye care regimens  4. Maintain client safety

Slide 163: MICROVASCULAR CX DIABETIC NEPHROPATHY  Progressive deterioration of kidney function

Slide 164: MICROVASCULAR CX DIABETIC NEPHROPATHY  HYPERGLYCEMIA causes the kidney filtration mechanism to be stressed  blood proteins leak into the urine  Pressure in the kidney blood vessels increases stimulate the development of nephropathy

Slide 165: MICROVASCULAR CX ASSESSMENT findings for diabetic nephropathy  1. Albuminuria  2. Anemia  3. Acidosis

Slide 166: MICROVASCULAR CX ASSESSMENT findings for diabetic nephropathy  4. Fluid volume overload  5. Oliguria  6. Hypertension  7. UTI

Slide 167: MICROVASCULAR CX NURSING MANAGEMENT 1. Assist in the control of hypertension- use of ACE inhibitor 2. Provide a low sodium and low protein diet 3. Administer prescribed medication for UTI

Slide 168: MICROVASCULAR CX NURSING MANAGEMENT  4. Assist in dialysis 5. Prepare patient for renal transplantation, if indicated

Slide 169: MICROVASCULAR CX Diabetic Neuropathy  A group of disorders that affect all type of nerves including the peripheral, autonomic and spinal nerves

Slide 170: MICROVASCULAR CX Diabetic Neuropathy  Two most common types of Diabetic Neuropathy are sensori-motor polyneuropathy and autonomic neuropathy

Slide 171: MICROVASCULAR CX Peripheral neuropathy- ASSESSMENT findings  1. paresthesias- prickling, tingling or heightened sensation  2. decreased proprioception  3. decreased sensation of light touch  4. unsteady gait  5. decreased tendon reflexes

Slide 172: MICROVASCULAR CX Peripheral neuropathy- Nursing Management  1. Provide teaching that good glucose control is very important to prevent its development  2. Manage the pain by analgesics, antidepressants and nerve stimulation

Slide 173: MICROVASCULAR CX Autonomic Neuropathy- ASSESSMENT findings  1. Silent, painless ischemia  2. delayed gastric emptying  3. orthostatic hypotension  4. N/V and bloating sensation  5. urinary retention  6. sexual dysfunction

Slide 174: MICROVASCULAR CX Autonomic Neuropathy-Nursing management  1. Educate about the avoidance of strenuous physical activity  2. Stress the importance of good glucose control to delay the development

Slide 175: MICROVASCULAR CX Autonomic Neuropathy-Nursing management  3. Provide LOW-fat, small frequent feedings  4. Administer bulk-forming laxatives for diabetic diarrhea  5. Provide HIGH-fiber diet for diabetic constipation

Slide 176: MICROVASCULAR CX MANAGEMENT OF FOOT AND LEG PROBLEMS Soft tissue injury in the foot/leg formation of fissures and callus  poor wound healing  foot/leg ulcer

Slide 177: MICROVASCULAR CX RISK FACTORS for the development of foot and leg ulcers  1. More than 10 years diabetic  2. Age of more than 40  3. Smoking  4. Anatomic deformities  5. History of previous leg ulcers or amputation

Slide 178: MICROVASCULAR CX MANAGEMENT of Foot Ulcers  Teach patient proper care of the foot  Daily assessment of the foot  Use of mirror to inspect the bottom

Slide 179: MICROVASCULAR CX MANAGEMENT of Foot Ulcers  Inspect the surface of shoes for any rough spots or foreign objects  Properly dry the feet  Instruct to wear closed-toe shoes that fit well, recommend use of low-heeled shoes

Slide 180: MICROVASCULAR CX MANAGEMENT  Instruct patient NEVER to walk barefoot, never to use heating pads, open-toed shoes and soaking feet  Trim toenails STRAIGHT ACROSS and file sharp corners  Instruct to avoid smoking and over-the counter medications and home remedies for foot problems

Article copyright - #1 source of information to update nurses all over the world. All rights reserved. No part of an article may be reproduced without the prior permission.


Philippine Nurses in Action

Search for Nursing Jobs Abroad!

Quick Nursing Facts:

NLE Results December 2011 Results

December 2011 Nursing Board Exam Successful Examinees for the December NLE 2011

Nursing Board Exam July 2010 NLE PRC

July 2011 Nursing Board Exam Successful Examinee PRC

List of Successful Examinees for Nursing Licensure Examination July 2011 Conducted by the PRC

We are one of the few websites to post results right after the Philippine Regulatory Board have release the list of successful examinees

Results for July 2011 NLE Board Exam

July 2011 NLE Nursing Licensure Examination Results List Of Passers

Recommended Books

Filipino Nurse Tag Rolls

NursingReview.Org Disclaimer

© 2008-2009 NurseReview.Org This site contains links to other Web sites. The owner of this blog has no control over the content or privacy practices of those sites. The information provided here is for general information purpose only. Comments are moderated. If in any case the owner approves a comment, it should not be taken as an endorsement of that comment. The owner doesn't claim full ownership of all photos or articles posted on this site. If the respective copyright owners wish for their photos or articles to be taken down, feel free to e-mail me and it will be taken down immediately.